Deng X, Ueda H, Su S B, Gong W, Dunlop N M, Gao J L, Murphy P M, Wang J M
Laboratory of Molecular Immunoregulation, Division of Basic Sciences, Intramural Research Support Program, SAIC Frederick, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD, USA.
Blood. 1999 Aug 15;94(4):1165-73.
Because envelope gp120 of various strains of human immunodeficiency virus type 1 (HIV-1) downregulates the expression and function of a variety of chemoattractant receptors through a process of heterologous desensitization, we investigated whether epitopes derived from gp120 could mimic the effect. A synthetic peptide domain, designated F peptide, corresponding to amino acid residues 414-434 in the V4-C4 region of gp120 of the HIV-1 Bru strain, potently reduced monocyte binding and chemotaxis response to macrophage inflammatory protein 1beta (MIP-1beta) and stromal cell-derived factor 1alpha (SDF-1alpha), chemokines that use the receptors CCR5 and CXCR4, respectively. Further study showed that F peptide by itself is an inducer of chemotaxis and calcium mobilization in human monocytes and neutrophils. In cross-desensitization experiments, among the numerous chemoattractants tested, only the bacterial chemotactic peptide fMLF, when used at high concentrations, partially attenuated calcium mobilization induced by F peptide in phagocytes, suggesting that this peptide domain might share a 7-transmembrane, G-protein-coupled receptor with fMLF. By using cells transfected with cDNAs encoding receptors that interact with fMLF, we found that F peptide uses an fMLF receptor variant, FPRL1, as a functional receptor. The activation of monocytes by F peptide resulted in downregulation of the cell surface expression of CCR5 and CXCR4 in a protein kinase C-dependent manner. These results demonstrate that activation of FPRL1 on human moncytes by a peptide domain derived from HIV-1 gp120 could lead to desensitization of cell response to other chemoattractants. This may explain, at least in part, the initial activation of innate immune responses in HIV-1-infected patients followed by immune suppression.
由于1型人类免疫缺陷病毒(HIV-1)不同毒株的包膜糖蛋白gp120通过异源脱敏过程下调多种趋化因子受体的表达和功能,我们研究了源自gp120的表位是否能模拟这种效应。一个合成肽结构域,称为F肽,对应于HIV-1布鲁毒株gp120的V4-C4区域中的氨基酸残基414-434,它能有效降低单核细胞对巨噬细胞炎性蛋白1β(MIP-1β)和基质细胞衍生因子1α(SDF-1α)的结合及趋化反应,这两种趋化因子分别利用CCR5和CXCR4受体。进一步研究表明,F肽本身就是人单核细胞和中性粒细胞趋化及钙动员的诱导剂。在交叉脱敏实验中,在所测试的众多趋化因子中,只有细菌趋化肽fMLF在高浓度使用时能部分减弱F肽在吞噬细胞中诱导的钙动员,这表明该肽结构域可能与fMLF共享一个7跨膜、G蛋白偶联受体。通过使用转染了编码与fMLF相互作用受体的cDNA的细胞,我们发现F肽使用一种fMLF受体变体FPRL1作为功能受体。F肽对单核细胞的激活导致CCR5和CXCR4的细胞表面表达以蛋白激酶C依赖的方式下调。这些结果表明,源自HIV-1 gp120的肽结构域对人单核细胞上FPRL1的激活可导致细胞对其他趋化因子反应的脱敏。这至少可以部分解释HIV-1感染患者先天免疫反应的初始激活随后出现免疫抑制的现象。